Orthobiologics Market Research Report - Forecast till 2030

Orthobiologics Market Report: Information by Product (Demineralized Bone Matrix, Bone Morphogenetic Protein), Application (Osteoarthritis & Degenerative Arthritis, Spinal Fusion), End User (Hospitals, Orthopedic Clinics)- Forecast till 2030

ID: MRFR/HC/6356-HCR | December 2022 | Region: Global | 85 Pages         

Orthobiologics Market

The orthobiologics market is expected to grow at a CAGR of 7.2% to reach USD 12.7 billion during the forecast period 2022-2030.

Segmentation

By Product Demineralized Bone Matrix Bone Morphogenetic Protein
By Application Osteoarthritis & Degenerative Arthritis Spinal Fusion
By End User Hospitals Orthopedic Clinics

Key Players

  • Arthrex Inc.
  • Exactech Inc.
  • Globus Medical Inc.
  • Integra LifeSciences
  • Johnson & Johnson
  • Medline Industries Inc.
  • NuVasive Inc.
  • Stryker Corporation
  • Wright Medical Group N.V.
  • Zimmer Biomet

Drivers

  • Increasing cases of trauma and sports injury
  • Demand for biologics in minimally invasive procedures
Speak to Analyst Request a Free Sample

Orthobiologics Market Overview


The orthobiologics market size is expected to reach USD 12.7 billion by 2030 at 7.2% CAGR during the forecast period 2022-2030. Trauma and sports injury occurrences have led to the demand for biologics in minimally invasive treatments. The enhancement in product development and product approval is driving the orthobiologics market growth.


The intensification of the senior population is getting more prone to diseases like osteoarthritis, which is expanding the orthobiologics market. Other factors like the awareness of orthobiologics and demand for improved therapy are key growth factors. A rise in obesity cases and sports and road accidents will further stimulate the market's growth.


Orthobiologics are referred to as regenerative cellular therapies. Orthobiological products include enhancing and stimulating the pain, tissue healing, and repairing ordinary functioning. Major growth factors that will boost the orthobiologics market in the forecast period are the concern of sports injuries and road accidents. Moreover, the increased spinal diseases and disorders cases are propelling the orthobiologics market.


Orthobiologics Market Segmentation


The orthobiologics market has been segmented on the basis of product, application, end-user, and region.


On the basis of product, the market has been classified as a Demineralized bone matrix (DBM), Bone morphogenetic protein (BPM), Allograft, Viscosupplementation products, Synthetic bone substitutes, and Others.


Based on application, the market has been divided into Osteoarthritis & degenerative arthritis, Spinal fusion, Fracture recovery, Soft tissue injuries, and Others. By application spinal fusion segment dominant, the market in 2018 due to increasing sports-related injuries, the prevalence of spine and traumatic injuries, and accidents.


By end user, the market has been segmented into Hospitals, Orthopedic Clinics, and Others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The orthobiologics market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European orthobiologics market has been segmented into Western Europe and Eastern Europe. Western Europe has been sub-segmented into Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The orthobiologics market in Asia-Pacific has been divided into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The orthobiologics market in the Middle East & Africa has been segmented into the Middle East and Africa.


Orthobiologics Regional Market Summary


Americas is likely to dominate the orthobiologics market during the forecast period owing to the advanced technologies, increasing funding & investments by major players, and rising prevalence of sports-related injuries & injuries caused due to falls and accidents. For instance, according to the report published by the American Orthopaedic Society for Sports Medicine in 2017, around 3.5 million kids below age 14 obtain medical treatment for sports injuries each year.


The European are likely to be the second-largest market in the orthobiologics market owing to the rising geriatric population, government funding and support of the healthcare sector coupled with increasing research and development, and rising awareness.


The Asia-Pacific market is expected to hold a significant share in the orthobiologics market. The market growth in this region can be attributed to the rise in demand for advanced treatment, awareness of orthobiologics, and rising investments in healthcare. Also, countries such as India and China are considering the fastest growing region due to a government focused toward adopting advance treatment from a developed country.


The market in the Middle East & Africa is expected to account for the smallest share of the global orthobiologics market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.


Orthobiologics Market Key Players

Some of the key players in the orthobiologics industry are Arthrex, Inc., Exactech, Inc., Globus Medical Inc., Integra LifeSciences, Johnson & Johnson, Medline Industries, Inc., NuVasive, Inc., Stryker Corporation, Wright Medical Group N.V., Zimmer Biomet, and Others

Recent Development


In May 2022


Ortho Regenerative Technologies Inc., a clinical-stage orthobiologics company, is focusing on the development of novel soft tissue repair regenerative technologies development. The company has announced that the United States Patent and Trademark Office will issue a patent related to the Company's ORTHO-R soft tissue repair platform.


The issued patent, titled Freeze-Dried Polymer Compositions, to mix with platelet-rich plasma and form implants for tissue repairing and composition for therapeutic intra-articular injection. It protects the composition and the method of use of Ortho R Technology.


In May 2022


Xtant Medical Holdings, Inc. is a medical technology company focusing on surgical solutions to treat spinal disorders. It has announced the appointment of Scott Neils as Chief Financial Officer, effective June 1, 2022.


Scott's success and experience in his tenure at Xtant, including the recent position as interim Chief Financial Officer, will make him a valuable team member.


Orthobiologics Global Market, by Product


  • Demineralized bone matrix (DBM)

  • Bone morphogenetic protein (BPM)

  • Allograft

  • Viscosupplementation products

  • Synthetic bone substitutes

  • Others


Orthobiologics Global Market, by Application


  • Osteoarthritis & degenerative arthritis

  • Spinal fusion

  • Fracture recovery

  • Soft tissue injuries

  • Others


Orthobiologics Global Market, by End User


  • Hospitals

  • Orthopedic Clinics

  • Others


Orthobiologics Global Market, by Region


  • Americas

    • North America

      • US

      • Canada



    • Latin America



  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe



  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • The Middle East & Africa

    • Middle East

    • Africa




Company Profiles       



  • Arthrex, Inc.

  • Exactech, Inc.

  • Globus Medical Inc

  • Integra LifeSciences

  • Johnson & Johnson

  • Medline Industries, Inc

  • NuVasive, Inc.

  • Stryker Corporation

  • Wright Medical Group N.V.

  • Zimmer Biomet

  • Others


Intended Audience



  • Orthobiologics Products Manufacturers

  • Orthobiologics Products Distributors and Suppliers

  • Healthcare Providers

  • Research Institutes and Academic Centers

  • Medical Devices Manufacturers

  • Government Associations

  • Market Research and Consulting 



Report Scope:

Report Attribute/Metric Details
  Market Size   USD 12.7 Billion
  CAGR   7.2%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Product, Application, End-user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Arthrex, Inc., Exactech, Inc., Globus Medical Inc., Integra LifeSciences, Johnson & Johnson, Medline Industries, Inc., NuVasive, Inc., Stryker Corporation, Wright Medical Group N.V., Zimmer Biomet, and Others
  Key Market Opportunities

  • Emerging technological innovations in biomaterials
  • Rising obese and geriatric population
  • Rising research and development activities by top players
  • Collaboration for the development of new products and launches by major players
  •   Key Market Drivers

  • Increasing cases of trauma and sports injury
  • Demand for biologics in minimally invasive procedures
  • Approval of products
  • Raising awareness


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Orthobiologics market is expected to reach USD 12.7 billion by 2030.

    Orthobiologics market is expected to exhibit a strong 7.2% CAGR over the forecast period from 2022 to 2030.

    Leading players in the orthobiologics market include Exactech, Arthrex, Globus Medical, Wright Medical Group, and Integra LifeSciences, among others.

    The Americas is the leading regional market for orthobiologics.

    The increasing demand for effective trauma healing agents for sports and muscle injuries is the major driver for the orthobiologics market.